

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1874409> since 2022-09-19T09:52:13Z

Published version:

DOI:10.1111/liv.15377

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Adipose tissue dysfunction and visceral fat are associated to hepatic insulin resistance and severity of NASH even in lean individuals

Chiara Saponaro¹ | Silvia Sabatini¹ | Melania Gaggini¹ | Fabrizia Carli¹ | Chiara Rosso² | Vincenzo Positano³ | Angelo Armandi² | Gian Paolo Caviglia² | Riccardo Faletti² | Elisabetta Bugianesi² | Amalia Gastaldelli^{1,2} | G. Saponaro^{1,3} | S. Sabatini¹ | M. Gaggini^{1,3} | F. Carli⁴ | C. Rosso⁵ | V. Positano⁴ | R. Younes^{???} radiologists, E. Bugianesi¹ | A. Gastaldelli.

¹Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy,

²University of Lille, France,

³ University of Siena, Italy.

⁴Division of Gastroenterology and Hepatology and Lab. of Diabetology, Dept. of Medical Sciences, University of Turin, Turin, Italy;

⁵ Fondazione Toscana Gabriele Monasterio, Pisa, Italy

Correspondence to:

Amalia Gastaldelli, PhD,
Head of Cardiometabolic Risk Unit
Institute of Clinical Physiology, CNR
via Moruzzi 1 56100 Pisa Italy
tel +39 050 3152679/80
fax +39 050 3152166
email amalia@ifc.cnr.it

Number of Tables: 0

Number of Figures: 4

Number of Supplementary Tables: 0

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Formattato: Non Apice / Pedice

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disorder associated with obesity and type 2 diabetes (T2D). There is also evidence of lean individuals with NAFLD and T2D, who presented with increased visceral fat (VF). However, it is unclear whether or not VF accumulation and dysfunction are the initiators of NAFLD onset and progression.

Objective: The aim of the study was to investigate the impact of VF vs. subcutaneous fat (SC-AT) in the onset and progression of NAFLD in lean, overweight, and obese individuals compared to lean controls.

Methods: Thirty-four non-diabetic NAFLD with liver biopsy and eight control individuals were enrolled in this study. Fat distribution such as VF, SC-AT, and hepatic fat (IHTG), was measured by magnetic resonance imaging (MRI). Free fatty acids (FFAs) and triglyceride (TAG) composition was assessed by mass spectrometry (MS), and lipolysis and insulin resistance were measured by tracer infusion.

Results: VF, but not SC-AT, was higher in lean NAFLD individuals compared to controls, and was associated with insulin resistance in liver, muscle and adipose tissue (Adipo-IR), increased lipolysis, and decreased adiponectin levels. As a consequence of lipid overflow increased IHTG was positively associated with high lipolysis, Adipo-IR, TG concentrations and increased ratio of saturated/unsaturated fatty acids. Moreover, VF was increased in NAFLD with low fibrosis and increased with the progression of liver disease.

Conclusions: Collectively, our results suggest VF accumulation as one of the “primum movens” of NAFLD, thus emphasizing that fat composition and distribution are key players in the regulation of lipid metabolism and NAFLD progression. These findings

propose VF as an early indicator of NAFLD, which may allow for evidence-based prevention and intervention strategies.

As soon as we finalized the figures, we will add the p values and r values to the results section of the abstract.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a highly heterogeneous metabolic disorder covering a wide spectrum of liver diseases that ranges from simple steatosis to progressive inflammation, fibrosis, and ballooning, resulting in non-alcoholic steatohepatitis (NASH) and cirrhosis [1-3]. The pathophysiology of the onset and progression of NAFLD is complex and is still not completely understood although it is established that NAFLD is a metabolic disease. In the last decades, a “multiple parallel hits hypothesis” has been proposed, in which not only excess calories and dietary components such as the westernized diet favor hepatic triglyceride accumulation and de novo fatty acid synthesis, but also the interactions between the liver and adipose tissue, together with the gut, play a concomitant role in the development of the disease. Although the VF depot is much smaller than the SC-AT it provides a foreground effect, by driving the release of FFAs directly into the portal circulation [2; 4; 5], possibly due to its enhanced lipolytic activity compared to that of SC-AT [6]. Indeed, the accumulation of lipids in the VF is often complemented with storage in other ectopic sites, such as the liver and the pancreas [7; 8]. Moreover, hepatic and circulating lipid composition may also affect the extent of liver damage, inflammation, and the rate of disease progression [9-12]. Finally, in this complex scenario, hepatic and peripheral (muscle and adipose tissue) insulin resistance are central, although a causal link between steatosis, VF accumulation and insulin resistance requires more investigation. Although various *in vivo*, *ex-situ* and *in vitro* models have been extensively used to study the role of VF and insulin resistance in NAFLD [13-16], these models don't represent the full spectrum of human NAFLD progression [17]. By contrast, numerous human studies, despite their translational value, are highly heterogeneous, due to ethnicity, sex, age, and the presence of confounding factors

such as concomitant metabolic diseases, with and without drug treatment. Moreover, these studies are often confronted with limiting factors in the methodology such as the accurate measurement of parameters including fat distribution and insulin resistance. Therefore, the use of stable-isotope methodology provides a more thorough mechanistic readout of lipid metabolism and insulin resistance [18; 19]. Collectively, these techniques combined with the diagnosis and staging of NAFLD by non-invasive imaging techniques [20; 21], will unveil whether or not VF accumulation and dysfunction are the initiators of NAFLD onset and progression.

Upon recruitment of a cohort of non-diabetic Italian patients with various stages of NAFLD, stratified for BMI, we set out to determine the interplay of VF and insulin resistance at different stages of NAFLD. Indeed, we forecasted that this subset of patients would offer a unique setting to assess the direct impact of fat distribution and dysfunction on hepatic insulin resistance and steatosis, independently of diabetes, an area that has not been adequately investigated.

Materials and Methods

Patients. Thirty-four non-diabetic subjects, with biopsy-proven NAFLD and eight controls (CT) were enrolled for the study that was part of the activities of the EU-FLIP project. Liver biopsies were scored according to Kleiner et al [22], altered fat topography, liver and pancreatic fat amount were measured by magnetic resonance imaging (MRI).

The study was approved by the ethics committee of the University Hospital San Giovanni Battista of Torino and was in accordance with the Helsinki Declaration. All subjects signed an informed consent form before participating to the study.

Plasma measurements. In all subjects we measured fasting plasma lipid profile, concentrations of FFA, triglycerides, total and HDL cholesterol, LDL, LFTs, apolipoprotein B (APO-B), apolipoprotein A1 (APO-A1), glucose, insulin and C-peptide, as previously reported [23; 24]. We also measured circulating concentrations of markers of inflammation and oxidative stress, e.g., MCP-1, and circulating adiponectin by Multiplex Assay based on Luminex Technologies.

Liver damage and fibrosis score. Liver biopsy was scored according to Kleiner et al [22]. The sum of grading for steatosis, lobular inflammation and hepatocellular ballooning was used to calculate the NAFLD activity score (NAS) from 0 to 8. Fibrosis was staged 0 to 4 and classified as absent (0), mild (1-2) and severe (3-4). NASH was defined by the local pathologist according to the joint presence of steatosis, hepatocyte ballooning and lobular inflammation with or without fibrosis.

Fat topography by magnetic resonance imaging. Magnetic resonance images were acquired using the DIXON method following protocols previously published [25; 26]. MRI images were acquired in DICOM format and then transferred to a dedicated workstation to be analyzed by an ad hoc developed software [27]. For each slice the subcutaneous abdominal fat area was measured by automatic detection of the outer and inner margins of subcutaneous adipose tissue as region of interest (ROI) from the cross-sectional images, and by counting the number of pixels between the outer and inner margins of subcutaneous adipose tissue; volume was automatically calculated by multiplying the slice area by the slice thickness and then the values of all slices were summed to obtain the abdominal fat volume. For each slice visceral (intra-abdominal) fat area and volume was determined with the use of histograms specific to

Commentato [AG1]: The radiologist should look at this part

Commentato [AG2]: Chiedere conferma al radiologo di Torino

the visceral region as previously described [27] and then summed to obtain the abdominal VF volume. A factor of 0.92 was used to convert adipose tissue volume into adipose tissue mass [25].

To quantify liver (LFF) and pancreatic (PFF) fat fraction the reconstructed fat and water image were analyzed using the OsiriX program [28]; 3 regions of interest (ROI) (30 × 30 mm) were quantified in the reconstructed fat and water images. Fat content was calculated from signal intensity in the ROIs of the reconstructed fat (S_{fat}) and water (S_{water}) images as $[S_{fat}/(S_{water} + S_{fat}) \times 100]$. [26]. Fat content was considered normal in liver if < 5.6% [29]

Metabolic indexes. Endogenous glucose production (EGP) and peripheral glucose clearance were measured by the kinetics of 6,6-D2-glucose infused for 2 hours during a fasting state, as previously reported [23; 30]. Hepatic insulin resistance (Hep-IR) reflects the inability of insulin to suppress fasting EGP and was calculated as the product of EGP x fasting insulin [24] while Muscle-IR was measured as the inverse of peripheral glucose clearance normalized by fasting insulin [30].

Lipolysis was measured by the kinetics of D5-glycerol infused for 2 hours during a fasting state, as previously reported [23; 30]. Adipose tissue insulin resistance reflects the inability of insulin to exert an antilipolytic action, leading to a relative increase in lipolysis and fasting FFA concentrations [31]. Lipo-IR was calculated as the product of fasting lipolysis x insulin while Adipo-IR was calculated as the product of fasting FFA x insulin [24; 31] [23; 31].

Metabolite analysis. Free fatty acid composition was evaluated by GC-MS (Agilent technology GC7890-MS5975). Briefly, separation of lipid fraction from 20uL of plasma

was carried out with a methanol and chloroform (2:1) solution using the Folch's method (REF). Fatty acids were derivatized to methyl-ester with a solution of methanol-BF₃ 14% and dried. Samples were reconstituted with 70 μ L heptane and 1 μ L was injected in the GC-MS. Total plasma FFA concentration was measured spectrophotometric ally on Beckman analyzer (Waco, Global Medical Instrumentation, Ramsey, MN). Single fatty acid concentration was determined using as internal standard a mix of ¹³C labeled FFA (Alga mix, CIL Cambridge MA, USA) and heptadecanoic acid. We quantified saturated (SFA, myristic, palmitic and stearic acid), and unsaturated (UFA, ie, the mono- unsaturated oleic and palmitoleic acids and the poly-unsaturated linoleic and arachidonic acids) fatty acid concentrations. The ratio of SFA/UFA were calculated as parameters of lipotoxicity.

Triglycerides (TGs) plasma composition was analyzed by ultra high pressure liquid chromatography/quadrupole time-of-flight mass spectrometry (UHPLC/Q-TOF, 1290 Infinity-6540 Agilent Technology, Santa Clara, CA) equipped with electrospray ionization (ESI). Plasma (20 μ L) was deproteinized with 200 μ L of cold methanol (Merck, Darmstadt, Germany), centrifuged at 14000 rpm for 20 minutes and the supernatant was transferred into glass vials and 1 μ L was injected into the LC/MS. Triglycerides were separated used an Agilent ZORBAX Eclipse Plus C18 2.1 \times 100 mm 1.8-Micron and acquisition was set in positive mode. TG species were analyzed using Agilent MassHunter Profinder B.06.00. Analysis of TG composition was qualitative: area of each specie was normalized to total area of triglycerides. TGs were classified as low unsaturated by calculating sum of areas of TGs with 0 and 1 double bonds (0-1 db) and unsaturated by calculating sum of areas of TGs with 2- 5 double bonds (2-5 db).

Statistical analysis. The variables were expressed as mean +/- standard error (SE).

The difference between groups was calculated using the parametric test (ANOVA) when normally distributed or using nonparametric test Mann-Whitney and Kruskal Wallis, when variables were not normally distributed (StatView, SAS Institute Inc). For correlation analysis, we used Pearson's correlation coefficient or Spearman's rank correlation respectively for normally distributed and not-normally distributed variables. Multiple correlation analyses was used to take into account the influence of covariates (as BMI); non normally distributed variables were Ln-transformed before analysis.

Silvia for heatmaps

Results

1. Clinical characteristics of study subjects

We studied thirty-four subjects with biopsy-proven NAFLD (20 NASH and 12 NAFL) with a wide range of BMI (n=10 with BMI <25; n=12 with BMI ≥ 25 and <30; n=12 with BMI ≥30) and eight lean controls (**Figure 1A**). Plasma levels of liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) were significantly higher in all NAFLD compared to the control group (ALT (U/l) 75.0±6.4 vs 16.3±1.6; AST (U/l) 45.7±6.2 vs 19.6±1.6; GGT (U/l) 105.9±21.2 vs 14.3±4.2, p<0.0002). Fasting glycemia, circulating FFAs and high density lipoprotein (HDL) were not significantly different among the 4 groups. Total TG, low density lipoprotein (LDL) and cholesterol were higher in NAFLD subjects compared to the controls, although no differences were found among lean, overweight, or obese NAFLD individuals.

2. Obesity, Adipose tissue distribution and insulin resistance

Subjects with NAFLD were divided into 3 groups according to their BMI. Compared to healthy lean subjects without NAFLD, lean NAFLD (BMI <25 kg/m²) had a similar BMI, while the BMI of overweight (BMI ≥ 25 and <30 kg/m²) and obese (BMI ≥ 30 kg/m²) individuals with NAFLD was significantly higher than CT and lean NAFLD (**Figure 1A**). Excessive intrahepatic triglyceride content (IHTG) (**Figure 1B**) and visceral fat (VF) (**Figure 1D**) measured by MRI were increased in all NAFLD compared to the lean controls. SC-AT, on the other hand, was significantly increased only in overweight and obese NAFLD, compared to the lean NAFLD and lean controls (**Figure 1C**). Obesity (BMI≥30 kg/m²) was associated to a further increase in all fat depots (**Figure 1B-D**).

Commentato [AG3]: Dire quanti sono NASH, penso quasi tutti




Fig 1. BMI (panel A) and fat distribution measured by MRI, i.e. IHTG (panel B), subcutaneous fat (panel C), visceral fat (panel D), in healthy controls and NAFLD subjects divided in accordance with their BMI (from light green to dark blue). Panel E shows the univariate correlation matrix between BMI, fat distribution, lipolysis and circulating TG and metabolic parameters in the entire cohort. Correlations that are not statistically significant (Pearson's $p > 0.05$) were crossed out. Mann Whitney's test $p < 0.05$, $** < 0.01$, $*** < 0.001$, $**** < 0.0001$.

Tracer infusion allowed the measurement of lipolysis, endogenous glucose production, insulin resistance in the liver (Hep-IR), muscle (Muscle-IR) and adipose tissue (as Adipo-IR and Lipo-IR).

Increased abdominal fat VF and SC-AT were positively correlated with lipolysis, which in turn was associated with increased FFA concentrations (Figure 1E). The associations were similar in NAFL and NASH. Indeed, the increased VF, SC-AT and total body lipolysis were associated to higher IHTG (Figure 1E).

Commentato [SS4]: Associato sia con ScF che con VF

In line with previous studies [24], we also found here that VF and SC-AT were strongly correlated with Hep-IR, and with a less extent to Muscle-IR (Figure 1E). Of note, VF was also inversely associated with circulating adiponectin levels (Figure 1E), the most abundant anti-inflammatory and atheroprotective adipokine secreted by adipose

tissues [32] that is also a marker of insulin sensitivity. However, we did not observe a correlation between SC-AT and adiponectin levels in line with previous studies [33; 34]. It has been already established that adiponectin reduces hepatic gluconeogenesis and increases glucose uptake and whole-body insulin sensitivity [35; 36]. Here, we found that adiponectin was significantly decreased in all NAFLD individuals compared to controls also in those with low BMI ($p < 0.02$), and it was inversely correlated with Hep-IR ($\rho = -0.50$, $p < 0.001$), and IHTG accumulation (**Figure 1E**), thus posing the possibility of an additional mechanism by which VF negatively impacts liver function and promotes NAFLD.

3. Adipose tissue distribution, circulating lipids and fatty acid composition

BMI was associated to increased lipolysis, but only VF and IHTG, but not SC-AT were associated to increased circulating TG (**Figure 1E**). Moreover, increased VF and IHTG, but not SC-AT, were associated with an increase in circulating ApoB (**Figure 1E**) indicating the increased synthesis and secretion of VLDL possibly stimulated by a high portal lipid supply [37; 38].

The analysis of FFA and TG composition showed a shift towards increased saturated TGs in NAFLD vs CT, but the increase was more pronounced in subjects with $\text{BMI} \geq 30$ (**Figure 2 A and 2 C**)

Saturated/unsaturated fatty acid ratio (in TG and FFA) was associated to increased Adipo-IR, Hep-IR, Muscle-IR and IHTG accumulation (**Figure 2E**).




Fig. 2 In panel A, B heatmap of circulating FFA concentration levels and ratio of saturated to unsaturated FFA (SFA/UFA) were reported in controls and NAFLD subjects divided by their BMI or degree of fibrosis, respectively. In panel C, D heatmap of circulating TGs grouped in accordance with the numbers of double bonds and saturated to unsaturated TAG ratio were reported in controls and NAFLD subjects divided by their BMI or degree of fibrosis, respectively. Values are reported as median within the groups and normalization was applied to the rows. In panel E Pearson's correlation matrix shows univariate association among the degree of saturation of FFA and TAG and metabolic parameters. Correlations that are not statistically significant (Pearson's p-value ≥ 0.05) were crossed out.

4. Adipose tissue distribution and severity of NAFLD

We analyzed body fat distribution according to the degree of fibrosis. Subjects with fibrosis 3-4 had higher BMI, hepatic fat, SC-AT and VF. In general VF, unlike SC-AT, was increased in all NAFLD individuals with or without fibrosis compared to lean controls ([Figure 3C and 3D](#)).

Commentato [SS5]: Già detto per IHTG, non mostrato per inflammation




Fig 3. BMI (panel A) and fat distribution measured by MRI, i.e. IHTG (panel B), subcutaneous fat (panel C), visceral fat (panel D), in healthy controls and NAFLD subjects divided in accordance with their degree of fibrosis (from pink to dark red). In panel E heatmap of metabolic parameters were reported in controls and NAFLD subjects divided by their degree of fibrosis. Values are reported as median within the groups and normalization was applied to the rows.

Hepatic fibrosis was associated also to higher adipose tissue dysfunction with increase adipose-tissue lipolysis, insulin resistance (Adipo-IT and Lipo-IR), circulating FFA and TG and reduced adiponectin levels (**Figure 3E**). Moreover, subjects with higher fibrosis had higher circulating saturated fatty acids both as FFA (**Figure 2B**) and TG (**Figure 2C**).

Discussion


Abdominal obesity is a known risk factor for the development of NAFLD since it's strictly related to peripheral and Hep-IR [24]. The rate of FFA mobilization from the adipocytes embedded within the deep abdominal adipose tissue is higher compared to SC-AT [39; 40], and previous studies suggested that VF is more strongly related to insulin resistance than SC-AT [41; 42]. The impaired antilipolytic effect of insulin on adipose tissue and the FFA efflux from the VF directly to the liver through the preferential portal vein, affects liver function, thus promoting steatosis. But whether VF accumulation is the cause or the consequence of the onset and development of NAFLD is still being debated. In this study, we corroborate a strong correlation between

VF accumulation and Hep-IR and HF accumulation, which occur also in lean NAFLD individuals, independently of T2D.

Although several studies demonstrated the involvement of VF in insulin resistance especially in the liver [43-48], there are conflicting data in this regard. We have shown that fasting EGP and gluconeogenesis were associated only to increased VF while Hep-IR and impaired insulin mediated suppression EGP were associated to both VF and IHTG [24]. Fabbrini et al. questioned the role of VF, compared to IHTG, in the association with insulin resistance [49]. However, the group matched for IHTG with high/low VF had a mean hepatic fat of 13.3% [49], i.e. double the limit for NAFLD. A reanalysis of the data by grouping the subjects from low IHTG-Low VF to high IHTG-high VF showed that insulin resistance is increased proportionally with both visceral and liver fat [2]. This was also confirmed in a recent study showed that high VF regardless of high or low IHTG was associated to higher risk of type 2 diabetes [50]. The preferential accumulation of fat and calories in visceral rather than subcutaneous fat, can be related to adipose tissue expansion, either by a combination of an increase in adipocyte number (hyperplasia), or size (hypertrophy). While hyperplasia is associated with a beneficial and protective asset of adipose tissue, hypertrophy results in increased inflammation, macrophage infiltration, and reduced insulin sensitivity [51-53]. Whether VF is more prone to expand in a hypertrophic manner and develop inflammation compared to SC-AT is still unclear. It has been proposed that VF and IHTG accumulation are the consequence of a dysfunctional SC-AT that limits peripheral adipose tissue expansion. The characteristics of the subcutaneous adipose tissue and the expression of lipid storage-related genes determines the expansion of subcutaneous adipose tissue in response to excessive caloric intake [54].

Lipodystrophy is often studied as a model of dysfunctional adipose tissue since it is associated with low subcutaneous fat and hepatic fat accumulation. Patients with generalized lipodystrophy have also low VF, while those with partial lipodystrophy have high VF [55]. Patients with severe lipodystrophy have also increased lipolysis and severe Hep-IR [56]. We have recently shown that the reduction of hepatic fat after pioglitazone treatment and the improvement in liver histology, was mediated by the decrease in VF and increase in SC-AT (ie by the VF/SC-AT ratio) [57]. These results indicate that the excess FFA that is not stored in the subcutaneous adipose tissue is then metabolized in the liver thus increasing hepatic TG accumulation.

Graphical abstract



It has been reported that lean NAFLD individuals had a higher amount of daily calory intake compared to lean controls [58-60]. Notably, the Diabetes Remission Clinical Trial (DiRECT) study recently revealed a significant and sustained improvement of T2D remission and β -cell function after a very low-calorie diet in patients with early onset of the disease. Calorie restriction produced a substantial weight-loss, which was associated with a decrease in hepatic and intra-pancreatic fat content [61; 62]. Therefore, reducing calory intake may be an efficient strategy to reduce VF

accumulation, thus avoiding the deleterious consequences that triggers the onset of Hep-IR and steatosis. The reason why an accumulation of VF occurs independent of weight-gain is not so clear. Some studies suggest that it may be related to stress associated with overeating or increased cortisol clearance. Genetics may also accentuate VF accumulation in response to stress [63].

Adipose tissue is not only a reservoir for energy storage and utilization, but also senses energy demands and secrete adipokines such as adiponectin, which exerts protective actions for liver injury by enhancing fatty acid β -oxidation, and reducing Hep-IR [64-67]. Studies on the association of adiponectin with visceral rather than subcutaneous fat have been conflicting [68-74]. Here, we showed that adiponectin levels were reduced in response to increased VF, and were inversely associated with increased Hep-IR, and steatosis. A significant decrease of circulating adiponectin was observed in lean NAFLD individuals compared to controls, thus suggesting that circulating levels of adiponectin as a potential biomarker to track development of NAFLD, VF accumulation and dysfunction. Thus, fat distribution is an important risk factor for the development and progression of NAFLD, because VF, unlike SC-AT, not only contributes to hepatic fatty acid overflow but it is significantly increased in the early stages of the disease.

Not only excessive caloric intake but also excess intake of saturated fat can be crucial in driving VF accumulation and liver damage. It is already known that different classes of lipids, according to their degree of saturation, can impact metabolism. An increased proportion of unsaturated compared to saturated fatty acids, i.e., a decreased SFA/UFA ratio in animal models, has been associated, with a favorable serum lipid profile and activation of hepatic enzymes involved in antioxidative pathways [75]. A diet high in UFA and low in SFA decreases fat accumulation in white adipose

tissue, and is associated with increased expression of hepatic lipolytic enzymes and enhanced fatty acid β -oxidation [76]. Target lipidomic analysis performed here revealed that novel lipid species may serve as early markers of liver damage such as SFA and saturated TG, independently of obesity. We also hypothesized that the SFA/UFA ratio could be considered as an index for the evaluation of metabolic health. Our results show that in NAFLD individuals the SFA/UFA ratio was significantly increased compared to healthy subjects indicating an imbalance in SFA in NAFLD, as previously suggested [12; 77-80]. These lipid alterations were strongly correlated with increased VF, Hep-IR and steatosis. These metabolic disturbances result in an increased demand for insulin secretion to 'overcome' insulin resistance, thus setting in place a vicious cycle. Indeed, insulin resistance is by definition tethered to higher levels of insulin than expected relative to the level of glucose.

In this study, we confirmed previous findings describing the relationship between VF and NAFLD, from larger cohorts of several countries with different ethnicity. The main strength of our study is that we investigated an Italian cohort of individuals with biopsy-proven NAFLD, excluding confounding factors strongly related to visceral adiposity, such diabetes and antidiabetic treatments, which influence fat accumulation and distribution [81-84]. We also stratified individuals by BMI, which allowed us to explore the pivotal role of VF on HF accumulation and damage, independently of body weight. Moreover, the use of tracer studies provided a more thorough understanding of the association of VF with hepatic and adipose tissue IR. A limitation of the study is the low number of patients recruited to a single center, but this was due to difficulties and costs to perform tracer studies and MRI scans in a large number of subjects. In addition, we did not perform analysis stratified by sex, because the women recruited in this study were less than men. Therefore, we cannot ignore

that sex differences can influence VF and SC-AT distribution, and correlation with HF content [39; 85]. Future studies on larger cohorts stratified for sex and BMI would be beneficial to study the onset and progression of lean NAFLD.

In conclusion, our findings indicate excess saturated fat and VF accumulation as the “primum movens” of NAFLD, therefore insinuating fat composition and distribution as key players in the regulation of lipid metabolism and NAFLD progression. A deeper investigation of fat distribution would be instrumental in defining the best targeted-interventional approach and to characterize patients at increased risk of disease development.

References

- [1] Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., et al., 2016. Pathophysiology of Non Alcoholic Fatty Liver Disease. *Int J Mol Sci* 17(12).
- [2] Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R.A., Bugianesi, E., Gastaldelli, A., 2013. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. *Nutrients* 5(5):1544-1560.
- [3] Marra, F., Lotersztajn, S., 2013. Pathophysiology of NASH: perspectives for a targeted treatment. *Curr Pharm Des* 19(29):5250-5269.
- [4] Saponaro, C., Gaggini, M., Carli, F., Gastaldelli, A., 2015. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. *Nutrients* 7(11):9453-9474.
- [5] Yki-Jarvinen, H., 2014. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol* 2(11):901-910.
- [6] Zierath, J.R., Livingston, J.N., Thorne, A., Bolinder, J., Reynisdottir, S., Lonnqvist, F., et al., 1998. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. *Diabetologia* 41(11):1343-1354.
- [7] Heber, S.D., Hetterich, H., Lorbeer, R., Bayerl, C., Machann, J., Auweter, S., et al., 2017. Pancreatic fat content by magnetic resonance imaging in subjects with prediabetes, diabetes, and controls from a general population without cardiovascular disease. *PLoS One* 12(5):e0177154.
- [8] Singh, R.G., Yoona, H.D., Wu, L.M., Lu, J., Plank, L.D., Petrov, M.S., 2017. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. *Metabolism* 69:1-13.
- [9] Dongiovanni, P., Stender, S., Pietrelli, A., Mancina, R.M., Cespiati, A., Petta, S., et al., 2018. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. *J Intern Med* 283(4):356-370.
- [10] Green, C.J., Hodson, L., 2014. The influence of dietary fat on liver fat accumulation. *Nutrients* 6(11):5018-5033.
- [11] Lytle, K.A., Bush, N.C., Triay, J.M., Kellogg, T.A., Kendrick, M.L., Swain, J.M., et al., 2019. Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity. *The Journal of clinical endocrinology and metabolism* 104(12):6171-6181.
- [12] Roumans, K.H.M., Lindeboom, L., Veeraiah, P., Remie, C.M.E., Phielix, E., Havekes, B., et al., 2020. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. *Nat Commun* 11(1):1891.
- [13] Akagiri, S., Naito, Y., Ichikawa, H., Mizushima, K., Takagi, T., Handa, O., et al., 2008. A Mouse Model of Metabolic Syndrome; Increase in Visceral Adipose Tissue Precedes the Development of Fatty Liver and Insulin Resistance in High-Fat Diet-Fed Male KK/Ta Mice. *J Clin Biochem Nutr* 42(2):150-157.
- [14] Franczyk, M.P., He, M., Yoshino, J., 2021. Removal of Epididymal Visceral Adipose Tissue Prevents Obesity-Induced Multi-organ Insulin Resistance in Male Mice. *J Endocr Soc* 5(5):bvab024.

- [15] Jones, P.H., Deng, B., Winkler, J., Zirnheld, A.L., Ehringer, S., Shetty, V., et al., 2019. Over-expression of miR-34c leads to early-life visceral fat accumulation and insulin resistance. *Sci Rep* 9(1):13844.
- [16] Yang, J., Park, K.W., Cho, S., 2018. Inhibition of the CD36 receptor reduces visceral fat accumulation and improves insulin resistance in obese mice carrying the BDNF-Val66Met variant. *J Biol Chem* 293(34):13338-13348.
- [17] Green, C.J., Parry, S.A., Gunn, P.J., Ceresa, C.D.L., Rosqvist, F., Piche, M.E., et al., 2018. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. *Horm Mol Biol Clin Investig* 41(1).
- [18] Blaak, E.E., 2017. Characterisation of fatty acid metabolism in different insulin-resistant phenotypes by means of stable isotopes. *Proc Nutr Soc*:1-7.
- [19] McCullough, A., Previs, S., Kasumov, T., 2018. Stable isotope-based flux studies in nonalcoholic fatty liver disease. *Pharmacol Ther* 181:22-33.
- [20] Hannah, W.N., Jr., Harrison, S.A., 2016. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology* 64(6):2234-2243.
- [21] Miele, L., Zocco, M.A., Pizzolante, F., De Matthaeis, N., Ainora, M.E., Liguori, A., et al., 2020. Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. *Metabolism* 112:154355.
- [22] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al., 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 41(6):1313-1321.
- [23] Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., et al., 2005. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. *Diabetologia* 48(4):634-642.
- [24] Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., et al., 2007. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. *Gastroenterology* 133(2):496-506.
- [25] Sironi, A.M., Gastaldelli, A., Mari, A., Ciociaro, D., Positano, V., Buzzigoli, E., et al., 2004. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. *Hypertension* 44(2):127-133.
- [26] Ishizaka, K., Oyama, N., Mito, S., Sugimori, H., Nakanishi, M., Okuaki, T., et al., 2011. Comparison of 1H MR spectroscopy, 3-point DIXON, and multi-echo gradient echo for measuring hepatic fat fraction. *Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine* 10(1):41-48.
- [27] Positano, V., Gastaldelli, A., Sironi, A.M., Santarelli, M.F., Lombardi, M., Landini, L., 2004. An accurate and robust method for unsupervised assessment of abdominal fat by MRI. *J Magn Reson Imaging* 20(4):684-689.
- [28] Rosset, A., Spadola, L., Ratib, O., 2004. OsiriX: an open-source software for navigating in multidimensional DICOM images. *J Digit Imaging* 17(3):205-216.
- [29] Szczepaniak, L.S., Nurenberg, P., Leonard, D., Browning, J.D., Reingold, J.S., Grundy, S., et al., 2005. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *American journal of physiology. Endocrinology and metabolism* 288(2):E462-468.
- [30] Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., et al., 2017. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients. *Diabetes, obesity & metabolism* 19(3):412-420.

- [31] Gastaldelli, A., Gaggini, M., DeFronzo, R.A., 2017. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. *Diabetes* 66(4):815-822.
- [32] Esfahani, M., Movahedian, A., Baranchi, M., Goodarzi, M.T., 2015. Adiponectin: an adipokine with protective features against metabolic syndrome. *Iran J Basic Med Sci* 18(5):430-442.
- [33] Konigorski, S., Janke, J., Drogan, D., Bergmann, M.M., Hierholzer, J., Kaaks, R., et al., 2019. Prediction of Circulating Adipokine Levels Based on Body Fat Compartments and Adipose Tissue Gene Expression. *Obes Facts* 12(6):590-605.
- [34] Gastaldelli, A., Sironi, A.M., Ciociaro, D., Positano, V., Buzzigoli, E., Giannessi, D., et al., 2005. Visceral fat and beta cell function in non-diabetic humans. *Diabetologia* 48(10):2090-2096.
- [35] Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., et al., 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 7(8):941-946.
- [36] Bugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., et al., 2005. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. *The Journal of clinical endocrinology and metabolism* 90(6):3498-3504.
- [37] Riches, F.M., Watts, G.F., Hua, J., Stewart, G.R., Naoumova, R.P., Barrett, P.H., 1999. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. *The Journal of clinical endocrinology and metabolism* 84(8):2854-2861.
- [38] Sniderman, A.D., Cianflone, K., 1993. Substrate delivery as a determinant of hepatic apoB secretion. *Arterioscler Thromb* 13(5):629-636.
- [39] Brand, T., van den Munckhof, I.C.L., van der Graaf, M., Schraa, K., Dekker, H.M., Joosten, L.A.B., et al., 2021. Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits. *J Clin Endocrinol Metab* 106(10):e3881-e3889.
- [40] Monzon, J.R., Basile, R., Heneghan, S., Udipi, V., Green, A., 2002. Lipolysis in adipocytes isolated from deep and superficial subcutaneous adipose tissue. *Obes Res* 10(4):266-269.
- [41] de Mutsert, R., Gast, K., Widya, R., de Koning, E., Jazet, I., Lamb, H., et al., 2018. Associations of Abdominal Subcutaneous and Visceral Fat with Insulin Resistance and Secretion Differ Between Men and Women: The Netherlands Epidemiology of Obesity Study. *Metab Syndr Relat Disord* 16(1):54-63.
- [42] Liu, L., Feng, J., Zhang, G., Yuan, X., Li, F., Yang, T., et al., 2018. Visceral adipose tissue is more strongly associated with insulin resistance than subcutaneous adipose tissue in Chinese subjects with pre-diabetes. *Curr Med Res Opin* 34(1):123-129.
- [43] Preis, S.R., Massaro, J.M., Robins, S.J., Hoffmann, U., Vasan, R.S., Irlbeck, T., et al., 2010. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. *Obesity* 18(11):2191-2198.
- [44] Alberti, K.G., Zimmet, P., Shaw, J., Group, I.D.F.E.T.F.C., 2005. The metabolic syndrome--a new worldwide definition. *Lancet* 366(9491):1059-1062.
- [45] Bosch, T.A., Dengel, D.R., Kelly, A.S., Sinaiko, A.R., Moran, A., Steinberger, J., 2015. Visceral adipose tissue measured by DXA correlates with measurement by CT and is associated with cardiometabolic risk factors in children. *Pediatr Obes* 10(3):172-179.

- [46] Krishnappa, S.K., Yashoda, H.T., Boraiah, G., Vishwa, S., 2015. Sagittal Abdominal Diameter to Measure Visceral Adipose Tissue in Overweight or Obese Adolescent Children and Its Role as A Marker of Insulin Resistance. *J Clin Diagn Res* 9(11):SC09-12.
- [47] Mendelson, M., Michallet, A.S., Monneret, D., Perrin, C., Esteve, F., Lombard, P.R., et al., 2015. Impact of exercise training without caloric restriction on inflammation, insulin resistance and visceral fat mass in obese adolescents. *Pediatr Obes* 10(4):311-319.
- [48] Pouliot, M.C., Despres, J.P., Nadeau, A., Moorjani, S., Prud'Homme, D., Lupien, P.J., et al., 1992. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. *Diabetes* 41(7):826-834.
- [49] Fabbrini, E., Magkos, F., Mohammed, B.S., Pietka, T., Abumrad, N.A., Patterson, B.W., et al., 2009. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. *Proc Natl Acad Sci U S A* 106(36):15430-15435.
- [50] Tejani, S., McCoy, C., Ayers, C.R., Powell-Wiley, T.M., Despres, J.P., Linge, J., et al., 2021. Cardiometabolic Health Outcomes Associated With Discordant Visceral and Liver Fat Phenotypes: Insights From the Dallas Heart Study and UK Biobank. *Mayo Clin Proc*.
- [51] Burhans, M.S., Hagman, D.K., Kuzma, J.N., Schmidt, K.A., Kratz, M., 2018. Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus. *Compr Physiol* 9(1):1-58.
- [52] Henninger, A.M., Eliasson, B., Jenndahl, L.E., Hammarstedt, A., 2014. Adipocyte hypertrophy, inflammation and fibrosis characterize subcutaneous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes. *PLoS One* 9(8):e105262.
- [53] Longo, M., Zatterale, F., Naderi, J., Parrillo, L., Formisano, P., Raciti, G.A., et al., 2019. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. *Int J Mol Sci* 20(9).
- [54] Alligier, M., Gabert, L., Meugnier, E., Lambert-Porcheron, S., Chanseau, E., Pilleul, F., et al., 2013. Visceral fat accumulation during lipid overfeeding is related to subcutaneous adipose tissue characteristics in healthy men. *The Journal of clinical endocrinology and metabolism* 98(2):802-810.
- [55] Polyzos, S.A., Perakakis, N., Mantzoros, C.S., 2019. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. *Metabolism* 96:66-82.
- [56] Petersen, K.F., Oral, E.A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., et al., 2002. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. *J Clin Invest* 109(10):1345-1350.
- [57] Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort-DeAguiar, R., et al., 2021. PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. *Liver international : official journal of the International Association for the Study of the Liver* 41(11):2659-2670.
- [58] Albhaisi, S., Chowdhury, A., Sanyal, A.J., 2019. Non-alcoholic fatty liver disease in lean individuals. *JHEP Rep* 1(4):329-341.
- [59] Jensen, T., Abdelmalek, M.F., Sullivan, S., Nadeau, K.J., Green, M., Roncal, C., et al., 2018. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. *J Hepatol* 68(5):1063-1075.
- [60] Sharp, K.P.H., Schultz, M., Coppel, K.J., 2018. Is non-alcoholic fatty liver disease a reflection of what we eat or simply how much we eat? *JGH Open* 2(2):59-74.
- [61] Taylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A.C., Aribisala, B.S., et al., 2018. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for beta Cell Recovery. *Cell Metab* 28(4):547-556 e543.

- [62] Taylor, R., Leslie, W.S., Barnes, A.C., Brosnahan, N., Thom, G., McCombie, L., et al., 2018. Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. *Diabetologia* 61(3):589-598.
- [63] Drapeau, V., Therrien, F., Richard, D., Tremblay, A., 2003. Is visceral obesity a physiological adaptation to stress? *Panminerva Med* 45(3):189-195.
- [64] Fiaschi, T., Buricchi, F., Cozzi, G., Matthias, S., Parri, M., Raugei, G., et al., 2007. Redox-dependent and ligand-independent trans-activation of insulin receptor by globular adiponectin. *Hepatology* 46(1):130-139.
- [65] Neumeier, M., Weigert, J., Schaffler, A., Weiss, T.S., Schmidl, C., Buttner, R., et al., 2006. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. *Biochem Biophys Res Commun* 350(3):731-735.
- [66] Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S., Cooper, G.J., 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *J Clin Invest* 112(1):91-100.
- [67] Inoue, M., Maehata, E., Yano, M., Taniyama, M., Suzuki, S., 2005. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. *Metabolism* 54(3):281-286.
- [68] Bidulescu, A., Liu, J., Hickson, D.A., Hairston, K.G., Fox, E.R., Arnett, D.K., et al., 2013. Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study. *BMC Cardiovasc Disord* 13:9.
- [69] Cho, S.A., Joo, H.J., Cho, J.Y., Lee, S.H., Park, J.H., Hong, S.J., et al., 2017. Visceral Fat Area and Serum Adiponectin Level Predict the Development of Metabolic Syndrome in a Community-Based Asymptomatic Population. *PLoS One* 12(1):e0169289.
- [70] Cnop, M., Havel, P.J., Utzschneider, K.M., Carr, D.B., Sinha, M.K., Boyko, E.J., et al., 2003. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia* 46(4):459-469.
- [71] Frederiksen, L., Nielsen, T.L., Wraae, K., Hagen, C., Frystyk, J., Flyvbjerg, A., et al., 2009. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. *The Journal of clinical endocrinology and metabolism* 94(10):4010-4015.
- [72] Gariballa, S., Alkaabi, J., Yasin, J., Al Essa, A., 2019. Total adiponectin in overweight and obese subjects and its response to visceral fat loss. *BMC Endocr Disord* 19(1):55.
- [73] Koh, S.J., Hyun, Y.J., Choi, S.Y., Chae, J.S., Kim, J.Y., Park, S., et al., 2008. Influence of age and visceral fat area on plasma adiponectin concentrations in women with normal glucose tolerance. *Clin Chim Acta* 389(1-2):45-50.
- [74] Korac, A., Srdic-Galic, B., Kalezic, A., Stancic, A., Otasevic, V., Korac, B., et al., 2021. Adipokine signatures of subcutaneous and visceral abdominal fat in normal-weight and obese women with different metabolic profiles. *Arch Med Sci* 17(2):323-336.
- [75] Kang, M.J., Shin, M.S., Park, J.N., Lee, S.S., 2005. The effects of polyunsaturated:saturated fatty acids ratios and peroxidisability index values of dietary fats on serum lipid profiles and hepatic enzyme activities in rats. *Br J Nutr* 94(4):526-532.
- [76] Liao, F.H., Liou, T.H., Shieh, M.J., Chien, Y.W., 2010. Effects of different ratios of monounsaturated and polyunsaturated fatty acids to saturated fatty acids on regulating body fat deposition in hamsters. *Nutrition* 26(7-8):811-817.
- [77] Alkhoury, N., Dixon, L.J., Feldstein, A.E., 2009. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. *Expert Rev Gastroenterol Hepatol* 3(4):445-451.
- [78] Berna, G., Romero-Gomez, M., 2020. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. *Liver Int* 40 Suppl 1:102-108.

- [79] Hodson, L., Rosqvist, F., Parry, S.A., 2020. The influence of dietary fatty acids on liver fat content and metabolism. *Proc Nutr Soc* 79(1):30-41.
- [80] Puri, P., Baillie, R.A., Wiest, M.M., Mirshahi, F., Choudhury, J., Cheung, O., et al., 2007. A lipidomic analysis of nonalcoholic fatty liver disease. *Hepatology* 46(4):1081-1090.
- [81] Koshizaka, M., Ishikawa, K., Ishibashi, R., Takahashi, S., Sakamoto, K., Yokoh, H., et al., 2021. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study. *Diabetes Ther* 12(1):183-196.
- [82] Koshizaka, M., Ishikawa, K., Ishikawa, T., Kobayashi, K., Takemoto, M., Horikoshi, T., et al., 2017. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). *BMJ Open* 7(5):e015766.
- [83] Shimabukuro, M., Tanaka, H., Shimabukuro, T., 2007. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. *J Hypertens* 25(4):841-848.
- [84] Xourgia, E., Papazafiropoulou, A., Melidonis, A., 2018. Effects of antidiabetic drugs on epicardial fat. *World J Diabetes* 9(9):141-148.
- [85] Golan, R., Shelef, I., Rudich, A., Gepner, Y., Shemesh, E., Chassidim, Y., et al., 2012. Abdominal superficial subcutaneous fat: a putative distinct protective fat subdepot in type 2 diabetes. *Diabetes Care* 35(3):640-647.

Figure legend

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

